SURVODUTIDE 10 MG - vial by Dragon Pharma, Europe SURVODUTIDE 10 MG - vial by Dragon Pharma, Europe SURVODUTIDE 10 MG - vial by Dragon Pharma, Europe
Peptides

SURVODUTIDE 10 MG

DUAL GLUCAGON AGONIST; GLP-1 AGONIST
ACTIVE SUBSTANCE: 10 MG SURVODUTIDE
FORM: 2 ML VIAL
ACTIVE HALF-LIFE: 109-115 HOURS
DOSAGE: MEN 0.6-4.8 MG/WEEK
ACNE: PERHAPS
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS

100.00 USD
Shipping From:
International
U.S. Domestic

SURVODUTIDE 10 MG Detailed

Trusted Dragon Pharma Survodutide Source

DragonPharma.Net offers genuine peptides from Dragon Pharma. Each 2 mL vial of Survodutide delivers a clinical-grade 10 mg dose of this advanced GLP-1 and glucagon receptor dual agonist.

Latest Survodutide Lab Test Results

dragon pharma survodutide lab test results 2024-09-13

What is Survodutide?

Survodutide is a next-generation peptide therapeutic engineered by Dragon Pharma to support fat loss, appetite regulation, and metabolic health. As a dual agonist of the GLP-1 and glucagon receptors, it enhances energy expenditure while reducing hunger signals, making it highly effective for individuals managing obesity, metabolic syndrome, or insulin resistance.

Learn more about Survodutide's mechanism of action and its clinical development path.

How to Use Survodutide

Administered via weekly subcutaneous injections, Survodutide is typically started at a low dose and titrated upwards over several weeks. This approach minimizes gastrointestinal discomfort while achieving optimal metabolic outcomes. Typical protocols escalate from 0.6 mg/week up to 4.8 mg/week across a 16–20 week ramp-up phase, followed by a maintenance cycle.

Dosage schedules should be individualized and supervised by a medical professional, especially for patients with comorbidities.

Example Survodutide Cycle

A standard example cycle begins with:

  • Weeks 1–4: 0.6 mg/week
  • Weeks 5–8: 1.2–2.4 mg/week
  • Weeks 9–12: 3.0–3.6 mg/week
  • Weeks 13–16: 4.8 mg/week (max dose)
  • Weeks 17–24: Maintain at 4.8 mg/week

Clinical benefits are most notable when Survodutide is paired with a caloric deficit and light physical activity.

Possible Adverse Effects

Survodutide is well tolerated by most users. Initial side effects can include fatigue, mild dizziness, and gastrointestinal symptoms such as nausea or bloating. These effects usually subside as the body adapts.

More serious side effects are rare but may include kidney strain or cardiovascular impacts in predisposed individuals. Periodic lab monitoring is advised, especially during prolonged use cycles.

Is Survodutide Right for You?

Survodutide may be a strong addition to any advanced fat-loss protocol. It's ideal for users looking to amplify body recomposition or support weight control where traditional strategies fall short.

Survodutide is available in our GLP-1 agonists category, alongside other peptides designed to enhance fat metabolism and appetite regulation.

Why Choose Dragon Pharma Survodutide?

Dragon Pharma is known for delivering research-backed peptides with high purity and consistent dosing. Whether you're an athlete cutting for a show or managing long-term weight loss, this is one of the most potent metabolic enhancers on the market.

Browse more Dragon Pharma gear trusted by athletes and biohackers worldwide.

Frequently Asked Questions About Survodutide

What does Dragon Pharma Survodutide do?

Survodutide by Dragon Pharma is designed to reduce appetite and increase energy usage by activating GLP-1 and glucagon receptors. This dual action helps promote fat loss and improve metabolic health.

How should I use Survodutide for weight loss?

Start with a low dose (0.6 mg weekly), then gradually increase up to 4.8 mg over several weeks. Survodutide is injected subcutaneously once per week. Always follow professional medical advice for dosage and cycle length.

Is Survodutide safe to use?

Survodutide is well tolerated by most users, especially when dosed correctly. Side effects like nausea or dizziness are possible early in the cycle, but these often subside. Monitoring is important, especially for kidney and heart function.

What are the side effects of Survodutide?

Common side effects include gastrointestinal discomfort, nausea, vomiting, dizziness, and fatigue. Most symptoms fade as the body adapts. Serious effects are rare but possible in individuals with pre-existing health issues.

Where can I buy Survodutide online?

You can purchase original Dragon Pharma Survodutide 10 mg from our secure online store. All products are shipped discreetly across the USA and come with verified lab results.

SURVODUTIDE 10 MG Reviews
R
Richard
Nov 23, 2024 (10:11)

Legit stuff that delivers fast results

Please log in to write SURVODUTIDE 10 MG review.

Related Offers
Lab Tested
US Domestic & International
SEMA-PEP 5 MG - vial by Dragon Pharma, Europe
Dragon Pharma, Europe

CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: SEMAGLUTIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~7 DAYS
DOSAGE: 0.25 - 0.5 MG/WEEK
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HIGH BLOOD PRESSURE (HBP)): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS

70.00 USD  
Coming Soon!
GHK-CU 10MG - vial by Dragon Pharma, Europe
Dragon Pharma, Europe

CLASSIFICATION: HUMAN PEPTIDE HORMONE
ACTIVE SUBSTANCE: GHK-CU
FORM: 2 ML VIAL x 10 MG
ACTIVE HALF-LIFE: ~ 30 MINUTES
DOSAGE: 2-3 TIMES PER WEEK
ACNE: NOT REPORTED
WATER RETENTION: NONE
HIGH BLOOD PRESSURE (HBP): NO KNOWN IMPACT
HEPATOTOXICITY: NONE
AROMATIZATION: DOES NOT AROMATIZE
MANUFACTURER: DRAGON PHARMA

Out of stock
Coming Soon!
AOD 9604 5MG - vial by Dragon Pharma, Europe
Dragon Pharma, Europe

CLASSIFICATION: FAT-BURNING PEPTIDE (GH FRAGMENT)
ACTIVE SUBSTANCE: AOD9604 (Fragment 176-191)
FORM: 2 mL VIAL × 5 MG
ACTIVE HALF-LIFE: ~4 HOURS
DOSAGE: MEN/WOMEN – 300–500 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA

Out of stock
Lab Tested
US Domestic & International
RETATRUTIDE - vial by Dragon Pharma, Europe
Dragon Pharma, Europe

CLASSIFICATION: GIP/GLP-1/GLUCAGON RECEPTOR TRIAGONIST
ACTIVE SUBSTANCE: RETATRUTIDE
FORM: 2 ML VIAL x 10 MG
ACTIVE HALF-LIFE: ~ 6 DAYS
DOSAGE: 0.5 MG/WEEK
ACNE: N/A
WATER RETENTION: N/A
HIGH BLOOD PRESSURE (HBP): N/A
HEPATOTOXICITY: N/A
AROMATIZATION: N/A
MANUFACTURER: DRAGON PHARMA
LABORATORY TESTED: VIEW LAB RESULTS

145.00 USD  
Lab Tested
US Domestic & International
TIRZE-PEP 5 MG - vial by Dragon Pharma, Europe
Dragon Pharma, Europe

CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HIGH BLOOD PRESSURE (HBP)): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS

90.00 USD  

Add in Cart - Product(s)

Close Button
Empty

Total Cost: